Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(7 years ago) | |
US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(4 years ago) | |
US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(6 months from now) | |
US7465800 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6281230 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(7 years ago) | |
US6555554 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(7 years ago) | |
US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(7 years ago) | |
US7119106 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Jul, 2016
(7 years ago) | |
US8589188 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6908432 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6045501 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US8204763 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6561976 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(4 years ago) | |
US6561977 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6315720 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
US8315886 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6755784 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US8626531 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US8404717 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(1 year, 1 month ago) | |
US7189740 | BRISTOL MYERS SQUIBB | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(1 year, 1 month ago) | |
US9056120 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(1 year, 1 month ago) | |
US9101622 | BRISTOL MYERS SQUIBB | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(1 year, 5 days ago) | |
US9101621 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(1 year, 5 days ago) | |
US8648095 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(1 year, 5 days ago) | |
US8530498 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(1 year, 5 days ago) | |
US9155730 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(1 year, 5 days ago) | |
US9393238 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(1 year, 5 days ago) | |
US7468363 | BRISTOL MYERS SQUIBB | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(7 months ago) | |
US8492406 | BRISTOL MYERS SQUIBB | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(7 months ago) | |
US7968569 | BRISTOL MYERS SQUIBB | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(7 months ago) | |
US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(3 years from now) |
Revlimid is owned by Bristol Myers Squibb.
Revlimid contains Lenalidomide.
Revlimid has a total of 32 drug patents out of which 29 drug patents have expired.
Expired drug patents of Revlimid are:
Revlimid was authorised for market use on 21 December, 2011.
Revlimid is available in capsule;oral dosage forms.
Revlimid can be used as use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl), use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds), use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities, use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds), use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide), treatment of male patient having a disease or condition responsive to a teratogenic drug, use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha, use of revlimid (lenalidomide) for the treatment of multiple myeloma, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct), use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
The generics of Revlimid are possible to be released after 08 March, 2028.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
New Indication(I-706) | Feb 17, 2018 |
New Indication(I-796) | May 28, 2022 |
New Indication(I-797) | May 28, 2022 |
Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
New Indication(I-672) | Jun 05, 2016 |
Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
New Strength(NS) | Jun 05, 2016 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds); Use of revlimid (lenalidomide) to inhibit the secretion of pro...
Dosage: CAPSULE;ORAL